Letter | Published:

Unopposed positive selection and autoreactivity in mice expressing class II MHC only on thymic cortex

Nature volume 383, pages 8185 (05 September 1996) | Download Citation

Subjects

Abstract

THE normal development of T cells in the thymus requires both positive and negative selection. During positive selection, thymocytes mature only if their T-cell receptors react with some specificity to host major histocompatibility complex (MHC) and host peptides. During negative selection, thymocytes die if their T-cell receptors react with too high an affinity to the presenting cell, self MHC, and peptides to which they are exposed. These two processes are important for the development of the T-cell repertoire and the acquisition of self-tolerance, but their precise location and temporal relationship are not known. We have used the keratin 14 (K14) promoter to re-express a class II MHC antigen (I-Ab) in class II-negative mice. The transgenic I-A molecule is expressed only on thymic cortical epithelium; thymic medullary epithelium and bone-marrow-derived cells are I-A negative. CD4+ cells are positively selected in K14 mice, but clonal deletion does not occur in K14 mice or in relB-negative mice, which lack a thymic medulla. The K14 CD4 cells are autoreactive, as they proliferate extensively to and specifically lyse I-Ab-positive target cells. These autoreactive cells make up 5% of the peripheral CD4 T cells, providing an estimate of the minimal frequency of positively selected cells that must subsequently undergo negative selection for self-tolerance to be preserved. Thus positive and negative selection occur in anatomically distinct sites.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    & Genes Dev. 5, 714–727 (1991).

  2. 2.

    et al. Cell 51, 175–187 (1987).

  3. 3.

    et al. Cell 53, 357–370 (1988).

  4. 4.

    , , & J. Immunol. 145, 1635–1645 (1990).

  5. 5.

    , , & Science 253, 1417–1420 (1991).

  6. 6.

    et al. Cell 66, 1051–1066 (1991).

  7. 7.

    et al. Nature 373, 531–536 (1995).

  8. 8.

    , , & J. Exp. Med. 154, 1652–1670 (1981).

  9. 9.

    et al. Cell 56, 27–35 (1989).

  10. 10.

    , , & Nature 340, 559–562 (1989).

  11. 11.

    et al. Nature 338, 765–768 (1989).

  12. 12.

    et al. Immunity 3, 657–666 (1995).

  13. 13.

    et al. J. Immunol. 151, 3954–3960 (1993).

  14. 14.

    & Nature 372, 100–103 (1994).

  15. 15.

    , & Cell 84, 521–529 (1996).

  16. 16.

    et al. Cell 84, 531–541 (1996).

  17. 17.

    , , , & Int. Immunol. 4, 707–710 (1992).

  18. 18.

    et al. Cell 58, 1035–1046 (1989).

  19. 19.

    , , & J. Exp. Med. 179, 2027–2031 (1994).

  20. 20.

    , , & Immunity 1, 385–391 (1994).

  21. 21.

    , , & Proc. Natl Acad. Sci. USA 92, 9851–9855 (1995).

  22. 22.

    , & Science 250, 1720–1723 (1990).

  23. 23.

    et al. Nature 336, 388–390 (1988).

  24. 24.

    J. Immunol. 126, 1614–1619 (1981).

Download references

Author information

Affiliations

  1. Department of Cancer Biology, Harvard School of Public Health, and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA

    • Terri M. Laufer
    • , Jay S. Markowitz
    •  & Laurie H. Glimcher
  2. Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA

    • Jenefer DeKoning
    •  & David Lo

Authors

  1. Search for Terri M. Laufer in:

  2. Search for Jenefer DeKoning in:

  3. Search for Jay S. Markowitz in:

  4. Search for David Lo in:

  5. Search for Laurie H. Glimcher in:

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/383081a0

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.